Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial
- 409 Downloads
Patients with frontal variant frontotemporal dementia (fvFTD) present with disinhibition, impulsiveness, apathy, altered appetite and stereotypic behaviors. A non-randomized clinical trial found improvement in these symptoms after treatment with a selective serotonin reuptake inhibitor (SSRI).
We aimed to subject a SSRI, paroxetine, to a more rigorous test of its efficacy using a double-blind, placebo-controlled experimental design.
Ten subjects meeting the consensus criteria for FTD were entered into a double-blind, placebo-controlled crossover trial. Doses of paroxetine were progressively increased to 40 mg daily. The same regimen was used for placebo capsules. Subjects were assessed with a battery of cognitive tests in the sixth week of paroxetine and placebo treatment. At each assessment, caregivers were interviewed using the Neuropsychiatric Inventory and asked to complete the Cambridge Behavioral Inventory.
There were no significant differences on the Neuropsychiatric Inventory or the Cambridge Behavioral Inventory. Paroxetine caused a decrease in accuracy on the paired associates learning task, reversal learning and a delayed pattern recognition task. There were no changes on the decision-making task, in spatial span, spatial recognition, spatial working memory, digit span and verbal fluency.
This study finds no evidence for the efficacy of paroxetine in the treatment of fvFTD. The results suggest that a chronic course of paroxetine may selectively impair paired associates learning, reversal learning and delayed pattern recognition. This pattern of deficits closely resembles that seen after tryptophan depletion. Results are discussed with respect to current theories on serotonergic modulation of orbitofrontal/ventromedial prefrontal cortex.
KeywordsDecision-making Frontotemporal dementia Paroxetine Serotonin
Funding was provided by a Wellcome Trust programme grant (019407) to Prof. T.W. Robbins, Prof. B.J. Everitt, Dr. A.C. Roberts and Prof. B.J. Sahakian and carried out within a MRC Center for Behavioural and Clinical Neuroscience. J.B.D. was funded by Merck Sharp and Dohme, a James Baird Award from the University of Cambridge School of Clinical Medicine and an Oon Khye Beng studentship. S.R. was funded by the MRC and the James Baird Fund. John Hodges funding was provided by a MRC program grant. The authors would like to thank Dr. S. Bozeat for help with collecting the data, Dr. M. Aitken for statistical advice and Prof. Robbins for his comments on the results.
- Blier P, de Montigny C (1999) Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 21:91S–98SGoogle Scholar
- Fowler KS, Saling MM, Conway EL, Semple JM, Louis WJ (1995) Computerized delayed matching to sample and paired associate performance in the early detection of dementia. Appl Neuropsychol 2:72–78Google Scholar
- Milner B (1964) Effects of different brain lesions on card sorting. Arch Neurol 9:100–110Google Scholar
- Montgomery SA (1996) Long-term management of obsessive-compulsive disorder. Int Clin Psychopharmacol 11[Suppl 5]:23–29Google Scholar
- Neary D, Snowden JS, Mann DM (2000) Classification and description of frontotemporal dementias. Ann New York Acad Sci 920:46–51Google Scholar
- Rogers RD, Blackshaw AJ, Middleton HC, Matthews K, Hawtin K, Crowley C, Hopwood A, Wallace C, Deakin JF, Sahakian BJ, Robbins TW (1999a) Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: implications for the monoaminergic basis of impulsive behaviour. Psychopharmacology 146:482–491PubMedGoogle Scholar
- Rogers RD, Everitt BJ, Baldacchino A, Blackshaw AJ, Swainson R, Wynne K, Baker NB, Hunter J, Carthy T, Booker E, London M, Deakin JF, Sahakian BJ, Robbins TW (1999b) Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. Neuropsychopharmacology 20:322–339PubMedGoogle Scholar